Morrone Louis H. 4

What Happened
Louis H. Morrone, Executive Vice President of Abbott Laboratories (ABT), was granted a total of 78,979 shares on February 24, 2026. The grant consists of 15,418 shares (restricted stock award) and 63,561 shares reported as a derivative/performance-based award; both were granted at $0 per share (compensation awards, not open-market purchases or sales).

Key Details

• Transaction date: February 24, 2026; Form 4 filed February 26, 2026 (filed within the typical 2-business-day window).
• Awards: 15,418 shares (RSU-type award) and 63,561 performance-based shares (derivative). Aggregate = 78,979 shares; grant price reported $0 (compensation).
• Vesting/conditions (Footnote F1): The 63,561 performance-based restricted stock award has a 3-year term, with no more than 1/3 vesting in any year and vesting tied to Abbott reaching a minimum return-on-equity target. The award allows shares to be withheld for tax purposes.
• Other footnotes: F2 references the balance in the Abbott Stock Retirement Trust as of Feb 24, 2026; F3 describes an employee stock option schedule under the 2017 Incentive Stock Program (exercisable in annual increments on Feb 24, 2027–2029).
• Shares owned after the reported transaction are not specified in the summary data provided in this request (see the filed Form 4 for full “amount owned following” details).

Context
These are company compensation awards (A = Award/Grant). Awards granted at $0 are routine executive compensation and do not represent a market purchase or sale. The larger portion is performance-based and will only vest if Abbott meets specified ROE targets over the 3-year performance period. For full disclosure and exact post-transaction holdings, consult the filed Form 4 (accession 0001867666-26-000002).